You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨雲頂新耀大升超15%創階段新高,伊曲莫德上市許可申請獲香港衞生署受理
格隆匯 12-03 11:32
雲頂新耀-B(1952.HK)今日逆勢上升,盤中一度升超15%至46.8港元,股價創2022年1月以來新高。公司昨晚宣佈,“伊曲莫德”(VELSIPITY)用於治療中重度活動性潰瘍性結腸炎成人患者的新藥上市許可申請,已獲得香港衞生署正式受理。該產品已於今年4月獲得澳門藥物監督管理局批准上市,並於10月份通過“港澳藥械通”政策在大灣區落地。雲頂新耀首席執行官羅永慶預計今年將在中國內地提交伊曲莫德的新藥上市許可申請,期待伊曲莫德在更多地區獲批,進一步擴大可及性,造福患者。(格隆匯)

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account